Quick Answer
REVIVA PHARMACEUTICALS HOLDINGS, INC. reported Net Income Loss of -$19.86 million for the year ending 2025.
- REVIVA PHARMACEUTICALS HOLDINGS, INC. showed an increase of +33.6% in Net Income Loss from 2024 to 2025.
- This data is from REVIVA PHARMACEUTICALS HOLDINGS, INC.'s annual report (Form 10-K), filed with the SEC on March 30, 2026.
- XBRL data for this metric is available from 2019 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 10 years of available data (2019 to 2025), REVIVA PHARMACEUTICALS HOLDINGS, INC.'s Net Income Loss has declined by 3,560.0%.
- Historical annual values: Fiscal year 2025: -$19.86 million | Fiscal year 2024: -$29.92 million | Fiscal year 2023: -$39.26 million | Fiscal year 2022: -$28.26 million | Fiscal year 2021: -$8.52 million | Fiscal year 2021: -$8.52 million | Fiscal year 2020: -$3.78 million | Fiscal year 2020: $617.9 thousand | Fiscal year 2019: -$846.8 thousand | Fiscal year 2019: $574.1 thousand.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: